National Medical Insurance Bureau: A total of more than 60 rare disease drugs in China have been approved for listing

The reporter learned from the 2021 China Rare Disease Conference on the 18th that since the establishment of the National Medical Security Bureau in 2018, it has dynamically adjusted the medical insurance drug catalogue once a year for 4 consecutive years, accumulatively including 507 new drugs and good drugs in the catalog, and achieving continuous expansion and structural optimization of the scope of drug protection through catalog adjustment. Up to now, more than 60 kinds of rare disease drugs in China have been approved for marketing, of which more than 40 have been included in the national medical insurance directory, involving 25 diseases.

Source: Xinhua News Agency Weibo